Влияние терапии бисфосфонатами на снижение риска кардиоваскулярных осложнений, ассоциированных с хронической сердечной недостаточностью, сахарным диабетом 2-го типа и остеопорозом у женщин в постменопаузе
Влияние терапии бисфосфонатами на снижение риска кардиоваскулярных осложнений, ассоциированных с хронической сердечной недостаточностью, сахарным диабетом 2-го типа и остеопорозом у женщин в постменопаузе
Тепляков А.Т., Березикова Е.Н., Шилов С.Н. и др. Влияние терапии бисфосфонатами на снижение риска кардиоваскулярных осложнений, ассоциированных с хронической сердечной недостаточностью, сахарным диабетом 2-го типа и остеопорозом у женщин в постменопаузе. Терапевтический архив. 2019; 91 (10): 63–69. DOI: 10.26442/00403660.2019.10.000162
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель исследования. Изучить эффективность пероральных бисфосфонатов (БФ) алендроната и ибандроната для профилактики сердечно-сосудистых осложнений у женщин в постменопаузе с сахарным диабетом (СД) 2-го типа и остеопорозом (ОП) в процессе 12-месячного проспективного наблюдения.
Материалы и методы. В исследование включены 86 женщин с ОП, хронической сердечной недостаточностью (ХСН) и СД 2-го типа: в 1-ю группу (n=52) вошли пациентки, получавшие базисную терапию при ХСН; во 2-ю группу (n=34) включены пациентки, которым дополнительно к базисной терапии ХСН назначались препараты алендроновой и ибандроновой кислот для лечения ОП. С целью выявления возможности ассоциации изученных факторов с характером течения СН больные разделены по итогам годичного наблюдения на две подгруппы: подгруппа А (n=49) – пациенты с благоприятным течением заболевания и подгруппа Б (n=37) – пациенты с неблагоприятным течением патологии.
Результаты и обсуждение. Через 12 мес в группе женщин, получавших терапию БФ, выявлено значимое снижение уровней предшественника мозгового натрийуретического пептида (NT-proBNP), фактора некроза опухоли-α и интерлейкина-1β по сравнению с исходными показателями. Выявлены значимые ассоциации уровней NT-proBNP (p=0,02) и исследованных цитокинов (p=0,01) с неблагоприятным течением ХСН. Также выявлена значимая ассоциация терапии БФ с благоприятным течением ХСН (p=0,01). Вероятность развития неблагоприятных сердечно-сосудистых событий в течение года при лечении ХСН препаратами базисной терапии с дополнительной терапией ОП БФ значимо (р=0,0025) ниже, чем лечение больных с ХСН только базисной терапией и не принимавших БФ для лечения ОП.
Заключение. У женщин в постменопаузе с ассоциированной сердечно-сосудистой патологией (ХСН, СД 2-го типа и ОП) профилактическая терапия оральными БФ алендронатом и ибандронатом эффективна, снижает риск прогрессирования ХСН, ингибирует медиаторы воспаления, положительно влияет на комбинированные конечные точки коморбидной сердечно-сосудистой патологии.
Ключевые слова: сердечная недостаточность, сахарный диабет, остеопороз, бисфосфонаты.
Materials and methods. The study included 86 women with osteoporosis, chronic heart failure (CHF) and type 2 diabetes: the 1st group (n=52) included patients who received basic therapy for heart failure; the 2nd group (n=34) included patients who, in addition to the basic therapy of heart failure, were prescribed alendronic and ibandronic acid preparations for the treatment of osteoporosis. In order to identify the possibility of associating the studied factors with the nature of the course of heart failure, the patients were divided according to the results of a one-year follow-up into two subgroups: subgroup A (n=49) – patients with a favorable course of the disease and subgroup B (n=37) – patients with an unfavorable course of pathology.
Results and discussion. After 12 months, a significant decrease in the levels of cerebral natriuretic peptide precursor (NT-proBNP), tumor necrosis factor-α, and interleukin-1β was found in the group of women treated with bisphosphonates compared to baseline. Significant associations of NT-proBNP levels (p=0.02) and the studied cytokines (p=0.01) with an unfavorable course of heart failure were revealed. A significant association of bisphosphonate therapy with a favorable course of heart failure (p=0.01) was also revealed. The probability of developing adverse cardiovascular events during the year in the treatment of heart failure with basic therapy drugs with additional therapy of osteoporosis with bisphosphonates is significantly (p=0.0025) lower than the treatment of patients with heart failure with only basic therapy and not taking bisphosphonates for the treatment of osteoporosis.
Conclusion. In postmenopausal women with associated cardiovascular pathology (CHF, type 2 diabetes and osteoporosis), prophylactic therapy with oral alendronate and ibandronate oral bisphosphonates is effective, reduces the risk of progression of heart failure, inhibits inflammatory mediators, positively affects the combined endpoints of comorbid cardiovascular pathology.
Keywords: heart failure, diabetes mellitus, osteoporosis, bisphosphonates.
Материалы и методы. В исследование включены 86 женщин с ОП, хронической сердечной недостаточностью (ХСН) и СД 2-го типа: в 1-ю группу (n=52) вошли пациентки, получавшие базисную терапию при ХСН; во 2-ю группу (n=34) включены пациентки, которым дополнительно к базисной терапии ХСН назначались препараты алендроновой и ибандроновой кислот для лечения ОП. С целью выявления возможности ассоциации изученных факторов с характером течения СН больные разделены по итогам годичного наблюдения на две подгруппы: подгруппа А (n=49) – пациенты с благоприятным течением заболевания и подгруппа Б (n=37) – пациенты с неблагоприятным течением патологии.
Результаты и обсуждение. Через 12 мес в группе женщин, получавших терапию БФ, выявлено значимое снижение уровней предшественника мозгового натрийуретического пептида (NT-proBNP), фактора некроза опухоли-α и интерлейкина-1β по сравнению с исходными показателями. Выявлены значимые ассоциации уровней NT-proBNP (p=0,02) и исследованных цитокинов (p=0,01) с неблагоприятным течением ХСН. Также выявлена значимая ассоциация терапии БФ с благоприятным течением ХСН (p=0,01). Вероятность развития неблагоприятных сердечно-сосудистых событий в течение года при лечении ХСН препаратами базисной терапии с дополнительной терапией ОП БФ значимо (р=0,0025) ниже, чем лечение больных с ХСН только базисной терапией и не принимавших БФ для лечения ОП.
Заключение. У женщин в постменопаузе с ассоциированной сердечно-сосудистой патологией (ХСН, СД 2-го типа и ОП) профилактическая терапия оральными БФ алендронатом и ибандронатом эффективна, снижает риск прогрессирования ХСН, ингибирует медиаторы воспаления, положительно влияет на комбинированные конечные точки коморбидной сердечно-сосудистой патологии.
Ключевые слова: сердечная недостаточность, сахарный диабет, остеопороз, бисфосфонаты.
________________________________________________
Materials and methods. The study included 86 women with osteoporosis, chronic heart failure (CHF) and type 2 diabetes: the 1st group (n=52) included patients who received basic therapy for heart failure; the 2nd group (n=34) included patients who, in addition to the basic therapy of heart failure, were prescribed alendronic and ibandronic acid preparations for the treatment of osteoporosis. In order to identify the possibility of associating the studied factors with the nature of the course of heart failure, the patients were divided according to the results of a one-year follow-up into two subgroups: subgroup A (n=49) – patients with a favorable course of the disease and subgroup B (n=37) – patients with an unfavorable course of pathology.
Results and discussion. After 12 months, a significant decrease in the levels of cerebral natriuretic peptide precursor (NT-proBNP), tumor necrosis factor-α, and interleukin-1β was found in the group of women treated with bisphosphonates compared to baseline. Significant associations of NT-proBNP levels (p=0.02) and the studied cytokines (p=0.01) with an unfavorable course of heart failure were revealed. A significant association of bisphosphonate therapy with a favorable course of heart failure (p=0.01) was also revealed. The probability of developing adverse cardiovascular events during the year in the treatment of heart failure with basic therapy drugs with additional therapy of osteoporosis with bisphosphonates is significantly (p=0.0025) lower than the treatment of patients with heart failure with only basic therapy and not taking bisphosphonates for the treatment of osteoporosis.
Conclusion. In postmenopausal women with associated cardiovascular pathology (CHF, type 2 diabetes and osteoporosis), prophylactic therapy with oral alendronate and ibandronate oral bisphosphonates is effective, reduces the risk of progression of heart failure, inhibits inflammatory mediators, positively affects the combined endpoints of comorbid cardiovascular pathology.
Keywords: heart failure, diabetes mellitus, osteoporosis, bisphosphonates.
Список литературы
1. Von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106(3):273-8. doi: 10.1016/s0002-9343(99)00028-5
2. Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res. 2000;15(10):1974-80. doi: 10.1359/jbmr.2000.15.10.1974
3. Mussolino ME, Gillum RF, Madans JH. Bone mineral density and stroke risk. Stroke. 2001;32(12):2956-7. doi: 10.1161/str.32.12.2956
4. Laroche M, Pécourneau V, Blain H, Breuil V, Chapurlat R, Cortet B, Sutter B, Degboe Y. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine. 2017;84(4):427-32. doi: 10.1016/j.jbspin.2016.09.022
5. Lee SH, Kim TS, Choi Y, Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008;41(7):495-510. doi: 10.5483/bmbrep.2008.41.7.495
6. Sprini D, Rini GB, Stefano LD, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014;11(2):117-9. doi: 10.11138/ccmbm/2014.11.2.117
7. Шилов С.Н., Тепляков А.Т., Яковлева И.В., Попова А.А., Березикова Е.Н., Гракова Е.В., Молоков А.В., Неупокоева М.Н., Кобец В.В., Копьева К.В., Гармаева О.В. Клиническая и патогенетическая взаимосвязь хронической сердечной недостаточности, сахарного диабета 2 типа и остеопороза. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):6-13 [Shilov SN, Teplyakov AT, Yakovleva IV, Popova AA, Berezikova EN, Grakova EV, Molokov AV, Neupokoeva MN, Kobets VV, Kopeva KV, Garmaeva OV. Clinical and pathogenic relationship between chronic heart failure, type 2 diabetes mellitus and osteoporosis. Kompleksnye Problemy Serdechno-Sosudistyh Zabolevanij. 2018;7(1):6-13 (In Russ.)]. doi: 10.17802/2306-1278-2018-7-1-6-13
8. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven J, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis. Vasc Health Risk Manag. 2009;5:185-97. doi: 10.2147/vhrm.s4822
9. Bastos Gonçalves F, Voûte MT, Hoeks SE, Chonchol MB, Boersma EE, Stolker RJ, Verhagen HJ. Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. Heart. 2012;98(13):988-94. doi: 10.1136/heartjnl-2011-301464
10. Асланян Н.С., Бланкова З.Н., Виценя М.В., Михайлов Г.В., Кулев Б.Д., Агеев Ф.Т. Взаимосвязь артериального кальциноза и остеопороза. Влияние терапии бисфосфонатами на сосудистую стенку. Сердце: журнал для практикующих врачей. 2016;3(15):151-60 [Aslanyan NS, Blankova ZN, Vicenya MV, Mihajlov GV, Kulev BD, Ageev FT. Interrelationship of arterial calcinosis and osteoporosis. The effect of bisphosphonate therapy on the vascular wall. Serdce: Zhurnal dlya Praktikuyushchih Vrachej. 2016;3(15):151-60 (In Russ.)]. doi: 10.18087/rhj.2016.3.2215
11. Christian RC, Harrington S, Edwards WD, Oberg AL, Fitzpatrick LA. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab. 2002;87(3):1062-7. doi: 10.1210/jcem.87.3.8354
12. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM, Weissleder R, Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31(16):1975-84. doi: 10.1093/eurheartj/ehq237
13. Tintut Y, Demer LL. Effects of bioactive lipids and lipoproteins on bone. Trends Endocrinol Metab. 2014;25(2):53-9. doi: 10.1016/j.tem.2013.10.001
14. Ярославцева М.В., Ульянова И.Н., Галстян Г.Р., Ильин А.В., Никанкина Л.В., Ремизов О.В., Дедов И.И. Система остеопротегерин (opg) лиганд рецептора-активатора ядерного фактора каппа-В (RANKL) у пациентов с сахарным диабетом, медиакальцинозом и облитерирующим атеросклерозом артерий нижних конечностей. Сахарный диабет. 2009;(1):25-32 [Yaroslavceva MV, Ul'yanova IN, Galstyan GR, Il'in AV, Nikankina LV, Remizov OV, Dedov II. The system of osteoprotegrin (OPG)/ligand of NF-kB receptor activator (RANKL) in patients with diabetes mellitus, mediacalcinosis and obliteratingatherosclerosis of lower leg arteries. Saharnyj Diabet = Diabetes Mellitus. 2009;(1):25-32 (In Russ.)]. doi: 10.14341/2072-0351-5416
15. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68(10):1243-51. doi: 10.1093/gerona/glt093
16. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006;22(3):465-75. doi: 10.1359/jbmr.061113
17. Magaziner J, Fredman L, Hawkes W, Hebel JR, Zimmerman S, Orwig DL, Wehren L. Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol. 2003;157(11):1023-31. doi: 10.1093/aje/kwg081
18. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20(10):1633-50. doi: 10.1007/s00198-009-0920-3
19. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380-90. doi: 10.7326/0003-4819-152-6-201003160-00008
20. Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor M, Tylavsky FA, Cummings SR, Harris TB, Newman AB; Health ABC Study. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res. 2007;22(7):1088-95. doi: 10.1359/jbmr.070409
21. Barbour KE, Boudreau R, Danielson ME, Youk AO, Wactawski-Wende J, Greep NC, LaCroix AZ, Jackson RD, Wallace RB, Bauer DC, Allison MA, Cauley JA. Inflammatory markers and the risk of hip fracture: the Women's Health Initiative. J Bone Miner Res. 2012;27(5):1167-76. doi: 10.1002/jbmr.1559
22. Ing SW, Orchard TS, Lu B, LaMonte MJ, Barbour KE, Cauley JA, Jackson RD. TNF Receptors Predict Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify This Association. J Clin Endocrinol Metab. 2015100(9):3380-7. doi: 10.1210/JC.2015-1662
23. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res. 2010;15(3):599-604. doi: 10.1359/jbmr.2000.15.3.599
24. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in Carotid Intima-Media Thickness after 1-Year Therapy with Etidronate for Osteopenia Associated with Type 2 Diabetes. J Clin Endocrinol Metab. 2000:85(8):2793-6. doi: 10.1210/jcem.85.8.6748
25. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis. 2004;44(4):680-8. doi: 10.1053/j.ajkd.2004.06.009
26. Kawahara T, Nishikawa M, Kawahara C, Inazu T, Sakai K, Suzuki G. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation. 2013;127(23):2327-35. doi: 10.1161/CIRCULATIONAHA.113.001534
27. Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, Spiering W. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. Atherosclerosis. 2016;252:106-15. doi: 10.1016/j.atherosclerosis.2016.06.039
28. Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013;24(1):271-7. doi: 10.1007/s00198-012-2213-5
29. Lu PY, Hsieh CF, Tsai YW, Huang WF. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther. 2011;33(9):1173-9. doi: 10.1016/j.clinthera.2011.07.012
30. Wolfe F, Bolster MB, O'Connor CM, Michaud K, Lyles KW, Colón-Emeric CS. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res. 2013;28(5):984-91. doi: 10.1002/jbmr.1792
31. Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause. 2009;16(4):689-93. doi: 10.1097/gme.0b013e318194cafd
32. Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates-a systematic review. Clin Med Insights Endocrinol Diabetes. 2012;5:47-54. doi: 10.4137/CMED.S10007
33. Kanazawa I, Yamaguchi T, Hayashi K, Takase H, Shimizu T, Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci. 2010;339(6):519-24. doi: 10.1097/MAJ.0b013e3181db6dfe
34. D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski MJ, Vetrovec GW, Frati G, Presutti DG, Quadri G, Moretti C, Gaita F, Zoccai GB. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis. 2013;226(1):178-85. doi: 10.1016/j.atherosclerosis.2012.10.065
35. Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord. 2009;10:113. doi: 10.1186/1471-2474-10-113
36. Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010;25(1):2-10. doi: 10.1359/jbmr.091201
37. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015;10(4):e0122646. doi: 10.1371/journal.pone.0122646
2. Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res. 2000;15(10):1974-80. doi: 10.1359/jbmr.2000.15.10.1974
3. Mussolino ME, Gillum RF, Madans JH. Bone mineral density and stroke risk. Stroke. 2001;32(12):2956-7. doi: 10.1161/str.32.12.2956
4. Laroche M, Pécourneau V, Blain H, Breuil V, Chapurlat R, Cortet B, Sutter B, Degboe Y. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine. 2017;84(4):427-32. doi: 10.1016/j.jbspin.2016.09.022
5. Lee SH, Kim TS, Choi Y, Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008;41(7):495-510. doi: 10.5483/bmbrep.2008.41.7.495
6. Sprini D, Rini GB, Stefano LD, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014;11(2):117-9. doi: 10.11138/ccmbm/2014.11.2.117
7. [Shilov SN, Teplyakov AT, Yakovleva IV, Popova AA, Berezikova EN, Grakova EV, Molokov AV, Neupokoeva MN, Kobets VV, Kopeva KV, Garmaeva OV. Clinical and pathogenic relationship between chronic heart failure, type 2 diabetes mellitus and osteoporosis. Kompleksnye Problemy Serdechno-Sosudistyh Zabolevanij. 2018;7(1):6-13 (In Russ.)]. doi: 10.17802/2306-1278-2018-7-1-6-13
8. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven J, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis. Vasc Health Risk Manag. 2009;5:185-97. doi: 10.2147/vhrm.s4822
9. Bastos Gonçalves F, Voûte MT, Hoeks SE, Chonchol MB, Boersma EE, Stolker RJ, Verhagen HJ. Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. Heart. 2012;98(13):988-94. doi: 10.1136/heartjnl-2011-301464
10. [Aslanyan NS, Blankova ZN, Vicenya MV, Mihajlov GV, Kulev BD, Ageev FT. Interrelationship of arterial calcinosis and osteoporosis. The effect of bisphosphonate therapy on the vascular wall. Serdce: Zhurnal dlya Praktikuyushchih Vrachej. 2016;3(15):151-60 (In Russ.)]. doi: 10.18087/rhj.2016.3.2215
11. Christian RC, Harrington S, Edwards WD, Oberg AL, Fitzpatrick LA. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab. 2002;87(3):1062-7. doi: 10.1210/jcem.87.3.8354
12. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM, Weissleder R, Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31(16):1975-84. doi: 10.1093/eurheartj/ehq237
13. Tintut Y, Demer LL. Effects of bioactive lipids and lipoproteins on bone. Trends Endocrinol Metab. 2014;25(2):53-9. doi: 10.1016/j.tem.2013.10.001
14. [Yaroslavceva MV, Ul'yanova IN, Galstyan GR, Il'in AV, Nikankina LV, Remizov OV, Dedov II. The system of osteoprotegrin (OPG)/ligand of NF-kB receptor activator (RANKL) in patients with diabetes mellitus, mediacalcinosis and obliteratingatherosclerosis of lower leg arteries. Saharnyj Diabet = Diabetes Mellitus. 2009;(1):25-32 (In Russ.)]. doi: 10.14341/2072-0351-5416
15. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68(10):1243-51. doi: 10.1093/gerona/glt093
16. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006;22(3):465-75. doi: 10.1359/jbmr.061113
17. Magaziner J, Fredman L, Hawkes W, Hebel JR, Zimmerman S, Orwig DL, Wehren L. Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol. 2003;157(11):1023-31. doi: 10.1093/aje/kwg081
18. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20(10):1633-50. doi: 10.1007/s00198-009-0920-3
19. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380-90. doi: 10.7326/0003-4819-152-6-201003160-00008
20. Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor M, Tylavsky FA, Cummings SR, Harris TB, Newman AB; Health ABC Study. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res. 2007;22(7):1088-95. doi: 10.1359/jbmr.070409
21. Barbour KE, Boudreau R, Danielson ME, Youk AO, Wactawski-Wende J, Greep NC, LaCroix AZ, Jackson RD, Wallace RB, Bauer DC, Allison MA, Cauley JA. Inflammatory markers and the risk of hip fracture: the Women's Health Initiative. J Bone Miner Res. 2012;27(5):1167-76. doi: 10.1002/jbmr.1559
22. Ing SW, Orchard TS, Lu B, LaMonte MJ, Barbour KE, Cauley JA, Jackson RD. TNF Receptors Predict Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify This Association. J Clin Endocrinol Metab. 2015100(9):3380-7. doi: 10.1210/JC.2015-1662
23. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res. 2010;15(3):599-604. doi: 10.1359/jbmr.2000.15.3.599
24. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in Carotid Intima-Media Thickness after 1-Year Therapy with Etidronate for Osteopenia Associated with Type 2 Diabetes. J Clin Endocrinol Metab. 2000:85(8):2793-6. doi: 10.1210/jcem.85.8.6748
25. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis. 2004;44(4):680-8. doi: 10.1053/j.ajkd.2004.06.009
26. Kawahara T, Nishikawa M, Kawahara C, Inazu T, Sakai K, Suzuki G. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation. 2013;127(23):2327-35. doi: 10.1161/CIRCULATIONAHA.113.001534
27. Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, Spiering W. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. Atherosclerosis. 2016;252:106-15. doi: 10.1016/j.atherosclerosis.2016.06.039
28. Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013;24(1):271-7. doi: 10.1007/s00198-012-2213-5
29. Lu PY, Hsieh CF, Tsai YW, Huang WF. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther. 2011;33(9):1173-9. doi: 10.1016/j.clinthera.2011.07.012
30. Wolfe F, Bolster MB, O'Connor CM, Michaud K, Lyles KW, Colón-Emeric CS. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res. 2013;28(5):984-91. doi: 10.1002/jbmr.1792
31. Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause. 2009;16(4):689-93. doi: 10.1097/gme.0b013e318194cafd
32. Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates-a systematic review. Clin Med Insights Endocrinol Diabetes. 2012;5:47-54. doi: 10.4137/CMED.S10007
33. Kanazawa I, Yamaguchi T, Hayashi K, Takase H, Shimizu T, Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci. 2010;339(6):519-24. doi: 10.1097/MAJ.0b013e3181db6dfe
34. D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski MJ, Vetrovec GW, Frati G, Presutti DG, Quadri G, Moretti C, Gaita F, Zoccai GB. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis. 2013;226(1):178-85. doi: 10.1016/j.atherosclerosis.2012.10.065
35. Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord. 2009;10:113. doi: 10.1186/1471-2474-10-113
36. Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010;25(1):2-10. doi: 10.1359/jbmr.091201
37. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015;10(4):e0122646. doi: 10.1371/journal.pone.0122646
2. Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res. 2000;15(10):1974-80. doi: 10.1359/jbmr.2000.15.10.1974
3. Mussolino ME, Gillum RF, Madans JH. Bone mineral density and stroke risk. Stroke. 2001;32(12):2956-7. doi: 10.1161/str.32.12.2956
4. Laroche M, Pécourneau V, Blain H, Breuil V, Chapurlat R, Cortet B, Sutter B, Degboe Y. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine. 2017;84(4):427-32. doi: 10.1016/j.jbspin.2016.09.022
5. Lee SH, Kim TS, Choi Y, Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008;41(7):495-510. doi: 10.5483/bmbrep.2008.41.7.495
6. Sprini D, Rini GB, Stefano LD, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014;11(2):117-9. doi: 10.11138/ccmbm/2014.11.2.117
7. Шилов С.Н., Тепляков А.Т., Яковлева И.В., Попова А.А., Березикова Е.Н., Гракова Е.В., Молоков А.В., Неупокоева М.Н., Кобец В.В., Копьева К.В., Гармаева О.В. Клиническая и патогенетическая взаимосвязь хронической сердечной недостаточности, сахарного диабета 2 типа и остеопороза. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):6-13 [Shilov SN, Teplyakov AT, Yakovleva IV, Popova AA, Berezikova EN, Grakova EV, Molokov AV, Neupokoeva MN, Kobets VV, Kopeva KV, Garmaeva OV. Clinical and pathogenic relationship between chronic heart failure, type 2 diabetes mellitus and osteoporosis. Kompleksnye Problemy Serdechno-Sosudistyh Zabolevanij. 2018;7(1):6-13 (In Russ.)]. doi: 10.17802/2306-1278-2018-7-1-6-13
8. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven J, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis. Vasc Health Risk Manag. 2009;5:185-97. doi: 10.2147/vhrm.s4822
9. Bastos Gonçalves F, Voûte MT, Hoeks SE, Chonchol MB, Boersma EE, Stolker RJ, Verhagen HJ. Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. Heart. 2012;98(13):988-94. doi: 10.1136/heartjnl-2011-301464
10. Асланян Н.С., Бланкова З.Н., Виценя М.В., Михайлов Г.В., Кулев Б.Д., Агеев Ф.Т. Взаимосвязь артериального кальциноза и остеопороза. Влияние терапии бисфосфонатами на сосудистую стенку. Сердце: журнал для практикующих врачей. 2016;3(15):151-60 [Aslanyan NS, Blankova ZN, Vicenya MV, Mihajlov GV, Kulev BD, Ageev FT. Interrelationship of arterial calcinosis and osteoporosis. The effect of bisphosphonate therapy on the vascular wall. Serdce: Zhurnal dlya Praktikuyushchih Vrachej. 2016;3(15):151-60 (In Russ.)]. doi: 10.18087/rhj.2016.3.2215
11. Christian RC, Harrington S, Edwards WD, Oberg AL, Fitzpatrick LA. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab. 2002;87(3):1062-7. doi: 10.1210/jcem.87.3.8354
12. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM, Weissleder R, Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31(16):1975-84. doi: 10.1093/eurheartj/ehq237
13. Tintut Y, Demer LL. Effects of bioactive lipids and lipoproteins on bone. Trends Endocrinol Metab. 2014;25(2):53-9. doi: 10.1016/j.tem.2013.10.001
14. Ярославцева М.В., Ульянова И.Н., Галстян Г.Р., Ильин А.В., Никанкина Л.В., Ремизов О.В., Дедов И.И. Система остеопротегерин (opg) лиганд рецептора-активатора ядерного фактора каппа-В (RANKL) у пациентов с сахарным диабетом, медиакальцинозом и облитерирующим атеросклерозом артерий нижних конечностей. Сахарный диабет. 2009;(1):25-32 [Yaroslavceva MV, Ul'yanova IN, Galstyan GR, Il'in AV, Nikankina LV, Remizov OV, Dedov II. The system of osteoprotegrin (OPG)/ligand of NF-kB receptor activator (RANKL) in patients with diabetes mellitus, mediacalcinosis and obliteratingatherosclerosis of lower leg arteries. Saharnyj Diabet = Diabetes Mellitus. 2009;(1):25-32 (In Russ.)]. doi: 10.14341/2072-0351-5416
15. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68(10):1243-51. doi: 10.1093/gerona/glt093
16. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006;22(3):465-75. doi: 10.1359/jbmr.061113
17. Magaziner J, Fredman L, Hawkes W, Hebel JR, Zimmerman S, Orwig DL, Wehren L. Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol. 2003;157(11):1023-31. doi: 10.1093/aje/kwg081
18. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20(10):1633-50. doi: 10.1007/s00198-009-0920-3
19. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380-90. doi: 10.7326/0003-4819-152-6-201003160-00008
20. Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor M, Tylavsky FA, Cummings SR, Harris TB, Newman AB; Health ABC Study. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res. 2007;22(7):1088-95. doi: 10.1359/jbmr.070409
21. Barbour KE, Boudreau R, Danielson ME, Youk AO, Wactawski-Wende J, Greep NC, LaCroix AZ, Jackson RD, Wallace RB, Bauer DC, Allison MA, Cauley JA. Inflammatory markers and the risk of hip fracture: the Women's Health Initiative. J Bone Miner Res. 2012;27(5):1167-76. doi: 10.1002/jbmr.1559
22. Ing SW, Orchard TS, Lu B, LaMonte MJ, Barbour KE, Cauley JA, Jackson RD. TNF Receptors Predict Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify This Association. J Clin Endocrinol Metab. 2015100(9):3380-7. doi: 10.1210/JC.2015-1662
23. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res. 2010;15(3):599-604. doi: 10.1359/jbmr.2000.15.3.599
24. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in Carotid Intima-Media Thickness after 1-Year Therapy with Etidronate for Osteopenia Associated with Type 2 Diabetes. J Clin Endocrinol Metab. 2000:85(8):2793-6. doi: 10.1210/jcem.85.8.6748
25. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis. 2004;44(4):680-8. doi: 10.1053/j.ajkd.2004.06.009
26. Kawahara T, Nishikawa M, Kawahara C, Inazu T, Sakai K, Suzuki G. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation. 2013;127(23):2327-35. doi: 10.1161/CIRCULATIONAHA.113.001534
27. Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, Spiering W. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. Atherosclerosis. 2016;252:106-15. doi: 10.1016/j.atherosclerosis.2016.06.039
28. Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013;24(1):271-7. doi: 10.1007/s00198-012-2213-5
29. Lu PY, Hsieh CF, Tsai YW, Huang WF. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther. 2011;33(9):1173-9. doi: 10.1016/j.clinthera.2011.07.012
30. Wolfe F, Bolster MB, O'Connor CM, Michaud K, Lyles KW, Colón-Emeric CS. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res. 2013;28(5):984-91. doi: 10.1002/jbmr.1792
31. Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause. 2009;16(4):689-93. doi: 10.1097/gme.0b013e318194cafd
32. Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates-a systematic review. Clin Med Insights Endocrinol Diabetes. 2012;5:47-54. doi: 10.4137/CMED.S10007
33. Kanazawa I, Yamaguchi T, Hayashi K, Takase H, Shimizu T, Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci. 2010;339(6):519-24. doi: 10.1097/MAJ.0b013e3181db6dfe
34. D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski MJ, Vetrovec GW, Frati G, Presutti DG, Quadri G, Moretti C, Gaita F, Zoccai GB. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis. 2013;226(1):178-85. doi: 10.1016/j.atherosclerosis.2012.10.065
35. Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord. 2009;10:113. doi: 10.1186/1471-2474-10-113
36. Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010;25(1):2-10. doi: 10.1359/jbmr.091201
37. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015;10(4):e0122646. doi: 10.1371/journal.pone.0122646
________________________________________________
2. Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res. 2000;15(10):1974-80. doi: 10.1359/jbmr.2000.15.10.1974
3. Mussolino ME, Gillum RF, Madans JH. Bone mineral density and stroke risk. Stroke. 2001;32(12):2956-7. doi: 10.1161/str.32.12.2956
4. Laroche M, Pécourneau V, Blain H, Breuil V, Chapurlat R, Cortet B, Sutter B, Degboe Y. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine. 2017;84(4):427-32. doi: 10.1016/j.jbspin.2016.09.022
5. Lee SH, Kim TS, Choi Y, Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008;41(7):495-510. doi: 10.5483/bmbrep.2008.41.7.495
6. Sprini D, Rini GB, Stefano LD, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014;11(2):117-9. doi: 10.11138/ccmbm/2014.11.2.117
7. [Shilov SN, Teplyakov AT, Yakovleva IV, Popova AA, Berezikova EN, Grakova EV, Molokov AV, Neupokoeva MN, Kobets VV, Kopeva KV, Garmaeva OV. Clinical and pathogenic relationship between chronic heart failure, type 2 diabetes mellitus and osteoporosis. Kompleksnye Problemy Serdechno-Sosudistyh Zabolevanij. 2018;7(1):6-13 (In Russ.)]. doi: 10.17802/2306-1278-2018-7-1-6-13
8. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven J, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis. Vasc Health Risk Manag. 2009;5:185-97. doi: 10.2147/vhrm.s4822
9. Bastos Gonçalves F, Voûte MT, Hoeks SE, Chonchol MB, Boersma EE, Stolker RJ, Verhagen HJ. Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. Heart. 2012;98(13):988-94. doi: 10.1136/heartjnl-2011-301464
10. [Aslanyan NS, Blankova ZN, Vicenya MV, Mihajlov GV, Kulev BD, Ageev FT. Interrelationship of arterial calcinosis and osteoporosis. The effect of bisphosphonate therapy on the vascular wall. Serdce: Zhurnal dlya Praktikuyushchih Vrachej. 2016;3(15):151-60 (In Russ.)]. doi: 10.18087/rhj.2016.3.2215
11. Christian RC, Harrington S, Edwards WD, Oberg AL, Fitzpatrick LA. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab. 2002;87(3):1062-7. doi: 10.1210/jcem.87.3.8354
12. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM, Weissleder R, Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31(16):1975-84. doi: 10.1093/eurheartj/ehq237
13. Tintut Y, Demer LL. Effects of bioactive lipids and lipoproteins on bone. Trends Endocrinol Metab. 2014;25(2):53-9. doi: 10.1016/j.tem.2013.10.001
14. [Yaroslavceva MV, Ul'yanova IN, Galstyan GR, Il'in AV, Nikankina LV, Remizov OV, Dedov II. The system of osteoprotegrin (OPG)/ligand of NF-kB receptor activator (RANKL) in patients with diabetes mellitus, mediacalcinosis and obliteratingatherosclerosis of lower leg arteries. Saharnyj Diabet = Diabetes Mellitus. 2009;(1):25-32 (In Russ.)]. doi: 10.14341/2072-0351-5416
15. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68(10):1243-51. doi: 10.1093/gerona/glt093
16. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006;22(3):465-75. doi: 10.1359/jbmr.061113
17. Magaziner J, Fredman L, Hawkes W, Hebel JR, Zimmerman S, Orwig DL, Wehren L. Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol. 2003;157(11):1023-31. doi: 10.1093/aje/kwg081
18. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20(10):1633-50. doi: 10.1007/s00198-009-0920-3
19. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380-90. doi: 10.7326/0003-4819-152-6-201003160-00008
20. Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor M, Tylavsky FA, Cummings SR, Harris TB, Newman AB; Health ABC Study. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res. 2007;22(7):1088-95. doi: 10.1359/jbmr.070409
21. Barbour KE, Boudreau R, Danielson ME, Youk AO, Wactawski-Wende J, Greep NC, LaCroix AZ, Jackson RD, Wallace RB, Bauer DC, Allison MA, Cauley JA. Inflammatory markers and the risk of hip fracture: the Women's Health Initiative. J Bone Miner Res. 2012;27(5):1167-76. doi: 10.1002/jbmr.1559
22. Ing SW, Orchard TS, Lu B, LaMonte MJ, Barbour KE, Cauley JA, Jackson RD. TNF Receptors Predict Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify This Association. J Clin Endocrinol Metab. 2015100(9):3380-7. doi: 10.1210/JC.2015-1662
23. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res. 2010;15(3):599-604. doi: 10.1359/jbmr.2000.15.3.599
24. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in Carotid Intima-Media Thickness after 1-Year Therapy with Etidronate for Osteopenia Associated with Type 2 Diabetes. J Clin Endocrinol Metab. 2000:85(8):2793-6. doi: 10.1210/jcem.85.8.6748
25. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis. 2004;44(4):680-8. doi: 10.1053/j.ajkd.2004.06.009
26. Kawahara T, Nishikawa M, Kawahara C, Inazu T, Sakai K, Suzuki G. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation. 2013;127(23):2327-35. doi: 10.1161/CIRCULATIONAHA.113.001534
27. Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, Spiering W. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis. Atherosclerosis. 2016;252:106-15. doi: 10.1016/j.atherosclerosis.2016.06.039
28. Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013;24(1):271-7. doi: 10.1007/s00198-012-2213-5
29. Lu PY, Hsieh CF, Tsai YW, Huang WF. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther. 2011;33(9):1173-9. doi: 10.1016/j.clinthera.2011.07.012
30. Wolfe F, Bolster MB, O'Connor CM, Michaud K, Lyles KW, Colón-Emeric CS. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res. 2013;28(5):984-91. doi: 10.1002/jbmr.1792
31. Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause. 2009;16(4):689-93. doi: 10.1097/gme.0b013e318194cafd
32. Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates-a systematic review. Clin Med Insights Endocrinol Diabetes. 2012;5:47-54. doi: 10.4137/CMED.S10007
33. Kanazawa I, Yamaguchi T, Hayashi K, Takase H, Shimizu T, Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci. 2010;339(6):519-24. doi: 10.1097/MAJ.0b013e3181db6dfe
34. D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski MJ, Vetrovec GW, Frati G, Presutti DG, Quadri G, Moretti C, Gaita F, Zoccai GB. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis. 2013;226(1):178-85. doi: 10.1016/j.atherosclerosis.2012.10.065
35. Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord. 2009;10:113. doi: 10.1186/1471-2474-10-113
36. Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010;25(1):2-10. doi: 10.1359/jbmr.091201
37. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015;10(4):e0122646. doi: 10.1371/journal.pone.0122646
Авторы
А.Т. Тепляков 1, Е.Н. Березикова 2, С.Н. Шилов 2, А.А. Попова 2, Е.Н. Самсонова 2, И.В. Яковлева 2, А.В. Молоков 2, Е.В. Гракова 1, К.В. Копьева 1
1 Научно-исследовательский институт кардиологии Томского национального исследовательского медицинского центра Российской академии наук, Томск, Россия;
2 ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России, Новосибирск, Россия
1 Cardiology Research Institute, Tomsk National Research Medical Center, Tomsk, Russia;
2 Novosibirsk State Medical University, Novosibirsk, Russia
1 Научно-исследовательский институт кардиологии Томского национального исследовательского медицинского центра Российской академии наук, Томск, Россия;
2 ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России, Новосибирск, Россия
________________________________________________
1 Cardiology Research Institute, Tomsk National Research Medical Center, Tomsk, Russia;
2 Novosibirsk State Medical University, Novosibirsk, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.